Company Overview and News


Add TEVVF
to your dashboard

Headline News

10 Blue-Chip Stocks That Could Wreck Your Retirement | InvestorPlace

15h investorplace
There’s an old saw on Wall Street that you don’t make a profit until you sell. Paper profits are meaningless. (300-0)

What We Can Learn From Teva's Q3 Report

2017-11-17 seekingalpha
Teva has to sell some of its businesses to (1) raise cash for debt repayment and (2) comply with FTC and EC regulations. (134-1)

Why AstraZeneca’s Revenues Rose in 3Q17

2017-11-16 marketrealist
As we saw in the first part of this series, AstraZeneca (AZN) released its 3Q17 earnings on November 9, 2017. It reported 3Q17 revenues of $6.2 billion, a rise of 10% at constant exchange rates compared to $5.7 billion in 3Q16. (129-0)

Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets 2 FDA Approvals, GW Pharmaceuticals' Price Target Lowered

2017-11-15 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (1487-5)

WVE / WAVE Life Sciences Ltd. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-15 fintel.io
WAVE Life Sciences Ltd. (NASDAQ:WVE) has 58 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 22,300,200 shares. Largest shareholders include Ra Capital Management, Llc, Redmile Group, LLC, Price T Rowe Associates Inc /md/, FMR LLC / Fidelity Management & Research, and Teva Pharmaceutical Industries Ltd. (136-0)

Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets Two FDA Approvals, GW Pharmaceuticals' Price Target Lowered

2017-11-15 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (1487-2)

Despite Valeant Improvement, VRX Stock Price Is Still Too High

2017-11-15 investorplace
Give credit where credit is due. New CEO Joe Papa has done a nice job in his efforts to turn around Valeant Pharmaceuticals Intl Inc (NYSE:VRX). So far, it hasn’t done much for the VRX stock price, which is basically flat so far in 2017. But flat performance in this market actually isn’t that bad. (324-0)

AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA

2017-11-15 zacks
AstraZeneca, plc (AZN - Free Report) announced that the FDA has granted approval to its asthma disease candidate, benralizumab. Benralizumab, approved as an add-on maintenance treatment for severe eosinophilic asthma in patients aged 12 years and older, will be marketed by the trade name of Fasenra. (237-0)

Healthcare Dogfight: GlaxoSmithKline Regains Top By Gains In November As O&M & Patterson Close-In

2017-11-14 seekingalpha
GSK regained top dog by net gains, while TEVJF led again by yield as calculated 11/13/17. (174-0)

Orexigen (OREX) Q3 Loss Narrower Than Expected, Stock Up

2017-11-14 zacks
Orexigen Therapeutics, Inc (OREX - Free Report) reported net loss of $1.35 per share for the third quarter of 2017, which was narrower than the Zacks Consensus Estimate of a loss of $2.13. The company had reported earnings of $1.12 in the year-ago period mainly due to a non-cash settlement gain of $80.2 million, which was recorded as deferred revenues previously. (163-0)

Deals of the day-Mergers and acquisitions

2017-11-14 reuters
Nov 14 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1100 GMT on Tuesday: (259-3)

Top Analyst Upgrades and Downgrades: Best Buy, Equifax, Gilead, MongoDB, NVIDIA, Rio Tinto, Teva, UPS and Many More

2017-11-13 247wallst
Stocks were indicated to open lower on Monday, with all major U.S. equity indexes down about 0.3% on average. What investors still need to consider is that the stock indexes have bumped up against all-time highs, and the trend that has dominated is that investors have bought every major sell-off for more than five years now. Investors are also looking for new investing and trading ideas to generate gains and income ahead. (385-1)

Teva's stock drops after J.P. Morgan downgrades to rare bearish rating - MarketWatch

2017-11-13 marketwatch
Shares of Teva Pharmaceutical Industries Ltd. TEVA, -0.59% shed 2.2% in premarket trade Monday, after the generic drug maker was downgraded at J.P. Morgan to a rare bearish rating, citing concerns over the U.S. generics business and growing debt levels. Analyst Chris Schott cut his rating to underweight, after being at neutral the past 10 months. Only 6% of companies covered by J.P. Morgan analysts have an underweight rating. (129-1)

UPDATE 1-Rough week for high-yield "junk" bond market; ETFs rebound a touch

2017-11-10 reuters
NEW YORK (Reuters) - Cracks in the red-hot U.S. high-yield bond market are starting to widen, with two junk-rated companies pulling their deals on Friday and U.S.-based high-yield funds suffering their second consecutive week of cash withdrawals. (138-0)

Short Sellers Back Way Off Major Pharma

2017-11-10 247wallst
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside. (289-1)

CUSIP: EP0496760